FDA Approves Generic Abortion Pill Amidst Criticism
The U.S. Food and Drug Administration (FDA) has approved a generic version of the abortion pill mifepristone, sparking criticism from anti-abortion groups and politicians. Evita Solutions' mifepristone, approved on October 2, 2025, can terminate pregnancies up to 10 weeks when taken with misoprostol.
The FDA's decision comes after a four-year wait since Evita Solutions first filed its application. The agency has faced pressure from abortion opponents, particularly under the Trump administration, to reevaluate mifepristone's safety. However, most major medical societies do not support restrictions on the drug.
Access to mifepristone remains restricted in many U.S. states due to abortion laws and ongoing lawsuits. The FDA has a history of delayed decisions on vaccines under the Trump administration, but officials stated they have limited discretion in deciding whether to approve a generic drug.
Evita Solutions' mifepristone is expected to launch in January 2023, providing another option for early pregnancy termination. The FDA's approval may face further challenges as abortion laws and politics continue to evolve in the U.S.
Read also:
- Rise in Flu Cases: Timing and Reasons Explored by Medical Experts for Flu Vaccination
- Nursing Infants: Advantages, Factors to Ponder, Guidelines, Essential Gear
- Anticipated Increase in Uninsured Residents to Pose Challenge for Local Healthcare Infrastructure
- Accusations of poor care and supposedly poor hygienic standards at LaSalle Hospital
